---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-020058"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:33:20.844004+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M

## Summary
- Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.
- Net loss improved to ($2.4M) from ($3.4M); loss per share ($0.02) vs ($0.03).
- Net cash used in operations ($2.0M) vs ($2.5M) in prior year.
- Expanded distribution with Hydrite Chemical; launched membrane treatment for dairy/beverage.
- Excluding share-based compensation, net loss was ($2.3M) vs ($3.1M).

## SEC filing metadata
- accession: 0001493152-25-020058
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315225020058/0001493152-25-020058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315225020058/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-020058
- JSON: https://secwatch.observer/filing/0001493152-25-020058.json
- Plain text: https://secwatch.observer/filing/0001493152-25-020058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.